Reaction

Chest Injury reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,020 reports · 46 co-occurring drugs

As of the last recalculation, Chest Injury appears in 2,020 FAERS reports alongside 46 co-occurring drug terms. The strongest observed disproportionality signal is TOBRAMYCIN SOLUTION (PRR 18.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Tobramycin Solution	21	18.2	18.2
Tobramycin Sulfate	21	17.6	17.7
Carboxymethylcellulose Sodium	13	14.3	14.4
Octreotide Acetate	38	13.0	13.0
Ampicillin	9	11.2	11.3
Ampicillin Sodium	9	11.2	11.3
Docusate Sodium 100Mg	25	10.9	10.9
Tobramycin	24	10.4	10.4
Moxifloxacin Hydrochloride	19	9.7	9.7
Calcium, Magnesium, Potassium, And Sodium Oxybates	8	9.6	9.6
Carisoprodol	16	8.7	8.7
Emicizumab	10	8.4	8.4
Erythromycin	15	8.3	8.3
Eplerenone	10	8.1	8.1
Pirfenidone	28	7.2	7.2
Minocycline	8	7.1	7.1
Letrozole Tablets	30	6.5	6.5
Dutasteride	5	6.3	6.4
Sodium Oxybate	38	6.0	6.0
Fesoterodine Fumarate	6	5.7	5.7
Ribociclib	17	5.6	5.6
Insulin Glulisine	5	5.1	5.1
Amphetamine	4	5.0	5.0
Armodafinil	10	4.9	4.9
Macitentan	32	4.8	4.8
Abemaciclib	9	4.7	4.7
Rasagiline Mesylate	5	4.6	4.6
Dolutegravir Sodium	4	4.6	4.6
Regorafenib	5	4.4	4.4
Dalfampridine	30	4.4	4.4
Teriparatide	44	4.1	4.1
Droxidopa	8	3.8	3.8
Ravulizumab	5	3.8	3.8
Abiraterone	5	3.8	3.8
Benralizumab	7	3.6	3.6
Travoprost	3	3.6	3.6
Siponimod	3	3.5	3.5
Teriflunomide	15	3.4	3.4
Dabigatran Etexilate	25	3.3	3.3
Dabigatran Etexilate Mesylate	23	3.3	3.3
Enzalutamide	16	2.8	2.8
Palbociclib	25	2.7	2.7
Elexacaftor, Tezacaftor, And Ivacaftor	3	2.5	2.5
Crizotinib	3	2.4	2.4
Relugolix	5	2.2	2.2
Abaloparatide	6	2.1	2.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.